Innovations in pharmaceutical policies and learnings for sustainable access to affordable medicines

References

• Anderson, M., Panteli, D., van Kessel, R., Ljungqvist, G., Colombo, F., & Mossialos, E. (2023). Challenges and opportunities for incentivising antibiotic research and development in Europe. The Lancet Regional Health–Europe, 33, 100705.
   PubMedGoogle Scholar
• Brinkhuis, F., Goettsch, W. G., Mantel-Teeuwisse, A. K., & Bloem, L. T. (2024). Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: Retrospective cohort study. BMJ, e077391.
   PubMedGoogle Scholar
• Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A. (2017). Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009–13. BMJ, 359(359), j4530. doi:10.1136/bmj.j4530
   PubMedGoogle Scholar
• Murray, C. J. L., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasi-Kangevari, M., Abd-Allah, F., Abdollahi, M., Abedi, P., Abedi, A., Abolhassani, H., Aboyans, V., Abreu, L. G., Abrigo, M. R. M., Abu-Gharbieh, E., Abu Haimed, A. K., Abushouk, A. I., Acebedo, A., Ackerman, I. N., Adabi, M., … Lim, S. S. (2020). Five insights from the global burden of disease study 2019. The Lancet, 396(10258), 1135–59. doi:10.1016/S0140-6736(20)31404-5
   PubMed Web of Science ®Google Scholar
• Romanello, M., Di Napoli, C., Drummond, P., Green, C., Kennard, H., Lampard, P., Scamman, D., Arnell, N., Ayeb-Karlsson, S., Ford, L. B., Belesova, K., Bowen, K., Cai, W., Callaghan, M., Campbell-Lendrum, D., Chambers, J., van Daalen, K. R., Dalin, C., Dasandi, N., … Costello, A. (2022). The 2022 report of the Lancet Countdown on health and climate change: Health at the mercy of fossil fuels. The Lancet, 400(10363), 1619–54. doi:10.1016/S0140-6736(22)01540-9
   PubMed Web of Science ®Google Scholar
• Sagan, A., Webb, E., Rajan, D., Karanikolos, M., & Scott, L. G. (2021). Health system resilience during the pandemic: It’s mostly about governance. Eurohealth, 27(1), 6 p.-10-5.
   Google Scholar
• Vogler, S. (2022a). Access to information in markets for medicines in the WHO European Region. Oslo Medicines Initiative technical report. World Health Organization. Regional Office for Europe. Retrieved March 8, 2024, from https://apps.who.int/iris/rest/bitstreams/1462628/retrieve
   Google Scholar
• Vogler, S. (2022b). Prices of new medicines: International analysis and policy options. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen.
   Google Scholar
• Vogler, S., Haasis, M. A., van den Ham, R., Humbert, T., Garner, S., & Suleman, F. (2021). European collaborations on medicine and vaccine procurement. Bulletin of the World Health Organization, 99(10), 715–21. doi:10.2471/BLT.21.285761
   PubMed Web of Science ®Google Scholar
• Vogler, S., Leopold, C., Zimmermann, N., Habl, C., & de Joncheere, K. (2014). The pharmaceutical pricing and reimbursement information (PPRI) initiative—experiences from engaging with pharmaceutical policy makers. Health Policy and Technology, 3(2), 139–48. doi:10.1016/j.hlpt.2014.01.001
   Web of Science ®Google Scholar
• Vogler, S., & Zimmermann, N. (2022). Improving medicines access in Brazil through collaboration in the PPRI network. Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, 13(2), 677. doi:10.30968/rbfhss.2022.132.0677
   Google Scholar
• Vogler, S., Zimmermann, N., Babar, Z.-U.-D., Busse, R., Espin, J., Mantel-Teeuwisse, A. K., Panteli, D., Suleman, F., & Wirtz, V. J. (2021). Addressing the medicines access challenge through balance, evidence, collaboration and transparency: Key take-away lessons of the 4th PPRI Conference. Journal of Pharmaceutical Policy and Practice, 14(1), 18. doi:10.1186/s40545-021-00300-3
   PubMed Web of Science ®Google Scholar
• Vogler, S., Zimmermann, N., Ferrario, A., Wirtz, V. J., de Joncheere, K., Pedersen, H. B., Dedet, G., Paris, V., Mantel-Teeuwisse, A. K., & Babar, Z.-U.-D. (2016). Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Journal of Pharmaceutical Policy and Practice, 9(1), 1. doi:10.1186/s40545-016-0056-8
   PubMedGoogle Scholar
• Vokinger, K. N., Hwang, T. J., Grischott, T., Reichert, S., Tibau, A., Rosemann, T., & Kesselheim, A. S. (2020). Prices and clinical benefit of cancer drugs in the USA and Europe: A cost–benefit analysis. The Lancet Oncology, 21(5), 664–70. doi:10.1016/S1470-2045(20)30139-X
   PubMed Web of Science ®Google Scholar
• Webb, E., Richardson, E., Vogler, S., & Panteli, D. (2022). What are the implications of policies increasing transparency of prices paid for pharmaceuticals? European Observatory on Health Care Systems. WHO Regional Office for Europe. Retrieved March 1, 2024, from https://apps.who.int/iris/rest/bitstreams/1423817/retrieve
   Google Scholar
• WHA. (2019, May 28). Resolution WHA 72.8: Improving the transparency of markets for medicines, vaccines, and other health products. Retrieved March 8, 2024, from https://apps.who.int/iris/bitstream/handle/10665/329301/A72_R8-en.pdf?sequence=1&isAllowed=y
   Google Scholar
• WHO. (2020). WHO Guideline on Country Pharmaceutical Pricing Policies (2nd ed.). World Health Organization. Retrieved March 1, 2024, from https://apps.who.int/iris/rest/bitstreams/1309649/retrieve
   Google Scholar
• Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., Möller, H., Moucheraud, C., Pécoul, B., Rägo, L., Rashidian, A., Ross-Degnan, D., Stephens, P. N., Teerawattananon, Y., 't Hoen, E. F. M., … Reich, M. R. (2017). Essential medicines for universal health coverage. The Lancet, 389(10067), 403–76. doi:10.1016/S0140-6736(16)31599-9
   PubMed Web of Science ®Google Scholar